Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-134 MAD study in healthy volunteers
NCT03742791Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing TS-134 with Placebo (2 arms). Primary endpoints: Incidence and Severity of Adverse Events, TS-134 Plasma Pharmacokinetic Profile - Cmax at Day 14 and 5 more. Started Jun 2016; status: completed.
02
Drugs
TS-134
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03742791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742791.